Efficacy of Der f 2/Zen 1‐LAMP1 Plasmid‐Based Vaccine Immunotherapy in Dogs With Atopic Dermatitis: A Proof‐of‐Concept Study
Open Access
- 24 November 2025
- journal article
- Published by Wiley in Veterinary Dermatology
- Vol. 37 (2) , 306-318
Abstract
Background: DNA‐based vaccination rapidly induces strong cellular and humoral immune responses, which may be enhanced by inclusion of lysosomal‐associated membrane protein‐1 (LAMP). Objectives: This proof‐of‐concept study evaluated the efficacy and safety of a Der f 2/Zen 1‐LAMP‐based DNA vaccine immunotherapy in client‐owned dogs with nonseasonal AD sensitised to Dermatophagoides farinae (Df) . Animals: Fifteen dogs positive for Df only and 20 dogs with reactivity to additional environmental allergens received either a low (0.5 mg/0.1 mL) or high (2 mg/0.4 mL) dose of the vaccine intradermally. Materials and Methods: Four doses of vaccine were administered every 2 weeks. Pruritus, Canine Atopic Dermatitis Extent and Severity Index (CADESI)‐04, average daily medication scores (AvdMS) and adverse events (AE) were recorded over 24 weeks. Owner perception of treatment efficacy (OGATE) was assessed at the end. Results: Pruritus and CADESI‐04 improved regardless of the sensitisation profile and the vaccine dose. After 24 weeks, despite a statistically insignificant reduction of AvdMS, 71%, 46% and 86% of dogs reached PVAS < 3.6, PVAS < 2 and CADESI‐04 < 10, respectively. There was no statistically significant effect of AvdMS on PVAS or CADESI‐04, meaning that the concurrently administered topical and/or systemic treatment(s) were unlikely to have been responsible for the observed PVAS and CADESI‐04 reduction. Twenty‐one owners (60%) rated the vaccine efficacy as good‐to‐excellent. No severe AEs were reported. Conclusions and Clinical Relevance: These results of this proof‐of‐concept study support not only the safety of DNA vaccine immunotherapy in dogs with AD, but also its potential clinical benefits. A double‐blinded, ≥ 12 month long, controlled study with more subjects should follow to further confirm the true efficacy of this vaccine.Keywords
Funding Information
- Nippon Zenyaku Kogyo
This publication has 29 references indexed in Scilit:
- Efficacy of a DNA vaccine encoding the E2 glycoprotein of bovine viral diarrhea virus 1 fused to mouse lysosome-associated membrane protein 1Veterinary Microbiology, 2024
- Immunotherapy and new treatmentsCurrent Opinion in Allergy and Clinical Immunology, 2024
- DNA Vaccines: History, Molecular Mechanisms and Future PerspectivesJournal of Molecular Biology, 2023
- Assessing Quality of Life for Pets with Dermatologic Disease and Their OwnersVeterinary Clinics of North America: Small Animal Practice, 2019
- Allergen immunotherapy in people, dogs, cats and horses – differences, similarities and research needsAllergy, 2018
- Single vs multiallergen sublingual immunotherapy in the polysensitized patient: a pilot studyInternational Forum of Allergy & Rhinology, 2018
- Safety and long-term immunological effects of CryJ2-LAMP plasmid vaccine in Japanese red cedar atopic subjects: A phase I studyHuman Vaccines & Immunotherapeutics, 2017
- The role and interpretation of pilot studies in clinical researchJournal of Psychiatric Research, 2011
- Sample size of 12 per group rule of thumb for a pilot studyPharmaceutical Statistics, 2005
- Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens.Proceedings of the National Academy of Sciences, 1995